VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
PDF
  • Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer [Elektronski vir] : an observational study
    Hochmair, Maximilian J ...
    Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & ... methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment [>/=]10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors.
    Vir: Future oncology. - ISSN 1744-8301 (Vol. 14, no. 27, Nov. 2018, str. 2861-2874)
    Vrsta gradiva - e-članek ; neleposlovje za odrasle
    Leto - 2018
    Jezik - angleški
    COBISS.SI-ID - 2048432753

    Povezava(-e):

    https://www.futuremedicine.com/doi/full/10.2217/fon-2018-0711?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed#
    DiRROS - Digitalni repozitorij raziskovalnih organizacij Slovenije
    DOI

Vnos na polico